triple negative disease

triple negative disease

Breast cancer in which malignant cells have no detectable estrogen receptors, progesterone receptors, or HER2 receptors.
Synonym: triple negative breast cancer.
Medical Dictionary, © 2009 Farlex and Partners
Mentioned in ?
References in periodicals archive ?
(4-5) Women diagnosed with triple negative disease tend to be of younger age (34% were 18-29 years of age), lower socioeconomic status, and are more obese when compared to hormone positive tumors (ER/PR+, HER2 negative).
The purpose was to assess the differences in survival and stage at diagnosis among hormone positive (ER/PR positive), HER2 positive, Triple Positive (ER/PR/ HER2 + and ER/HER2 +), and Triple Negative disease (ER/PR/ HER2 negative) in a 12 year period.
Seventy two percent of the patients were hormone positive (ER/PR positive), while 14% of the population was diagnosed with triple negative disease (Table I).
However, the rate of African American patients diagnosed with triple negative disease was significantly higher when compared to the Caucasian population (30% vs.
When evaluating the five year overall survival for the triple negative disease group versus all other hormone/HER2 groups with local disease (Stage I+II) and regional disease (Stage III), there was a significant decrease in survival for the TNBC group at each stage (p value 0.03 and 0.02 respectively) (Figure III).
(10), which revealed that African Americans developed the highest rate of triple negative disease when compared to Hispanics and Caucasians at all age groups.
In patients with triple negative disease, 5 of 7 (71%) analysed samples expressed GPNMB, 7 of 9 (78%) evaluable patients had tumour shrinkage, and the median PFS for these patients was 17.9 weeks.
Gallen International Expert Consensus.[sup][3] The panel supported the clinicopathological determination of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki-67 to define subtypes of primary breast cancer as Luminal A, Luminal B, HER2-positive, and triple negative diseases. The transition to the predominance of tumor biology rather than numerical disease indicators such as tumor size or extent of nodal involvement was finalized by the panel.

Full browser ?